TABLE 1.
Unadjusted OR for HPV infection and HPV-16 serology in control women according to cervical pathology
| Cervical disease status | No. of women in group | % of women positive for HPV DNA | OR (95% CI) | No. (%) of women positive for HPV-16 IgG | OR (95% CI) | No. (%) of women positive for HPV-16 IgA | OR (95% CI) |
|---|---|---|---|---|---|---|---|
| Control women (no cancer) | |||||||
| Normal | 848 | 20.4 | 1.0 | 772 (43.8) | 1.0 | 767 (27.1) | 1.0 |
| ASCUS | 82 | 42.7 | 2.9 (1.7-4.8) | 70 (44.3) | 1.0 (0.6-1.7) | 71 (45.1) | 2.2 (1.3-3.6) |
| LSIL | 40 | 70.0 | 9.0 (4.2-19.4) | 36 (63.9) | 2.3 (1.1-4.6) | 36 (25) | 0.9 (0.4-1.9) |
| HSIL | 33 | 75.8 | 12.2 (5.4-27.5) | 30 (26.7) | 0.5 (0.2-1.1) | 30 (33.3) | 1.3 (0.6-2.9) |
| Total | 1,003 | 26.1 | 908 (44.1) | 904 (28.7) | |||
| Cancer | 474 | NDa | 474 (61.8) | 2.1 (1.6-2.6) | 474 (52.7) | 2.8 (2.2-3.5) |
a
ND, not determined (tissue for HPV typing was not available from cancer patients).